Filing Flows › Sutro Biopharma (STRO) › Q4 2025
Sutro Biopharma (STRO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 23, 2026
Sutro Biopharma (STRO) reported revenue of $11.6M for the fourth quarter 2025 (Q4 2025), -21% from a year earlier and +20% from the quarter before. Operating margin was -326.7%, net loss $46.8M (401.5% of revenue).
Sutro Biopharma, Q4 2025: revenue $11.6M (-21% year over year), operating margin -326.7%, net loss $46.8M, operating cash flow −$26.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.6M | +20% | -21% |
| Operating profit | −$38.0M | — | — |
| Net earnings | −$46.8M | — | — |
| Operating cash flow | −$26.4M | — | — |
What changed
Revenue was $11.6M in Q4 2025, down 21% year over year and up 20% from the previous quarter.
Operating costs exceeded revenue by $38.0M, an operating margin of -326.7%. Total costs fell 38% while revenue fell 21%. The quarter ended with a net loss of $46.8M, narrower than the previous quarter's $56.9M loss.
Operating cash flow was −$26.4M. Non-cash charges added back $1.6M of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items added $17.0M.
Questions
What was Sutro Biopharma's revenue in the fourth quarter 2025?
Sutro Biopharma (STRO) reported revenue of $11.6M for the fourth quarter 2025 (Q4 2025), -21% from a year earlier and +20% from the quarter before.
Was Sutro Biopharma profitable in the fourth quarter 2025?
Operating loss was $38.0M (-326.7% of revenue) and net loss $46.8M.
Source: Sutro Biopharma 10-K on SEC EDGAR.